71432-05-8Relevant academic research and scientific papers
Access to α,β-unsaturated carboxylic acids through water-soluble palladium catalyzed hydroxycarbonylation of alkynes using water as the solvent
Gao, Mingjie,Jia, Xiaofei,Lv, Jinhe,Ren, Xinyi,Song, Jiaxin,Xie, Congxia,Zhang, Jinrong,Zhang, Kai,Zhao, Jinyu,Zhou, Ziqin,Zong, Lingbo
, p. 4708 - 4713 (2021/07/26)
A sulfoxantphos modified palladium-catalyzed synthesis of α,β-unsaturated carboxylic acids from alkynes with CO and H2O was described. The atom-economic hydroxycarbonylation of various symmetrical and unsymmetrical alkynes can be achieved with chemo-, stereo-, and regioselectivity, affording the corresponding carboxylic acids in good to excellent yields. Using water as the reaction solvent, the water-soluble palladium catalyst was easily separated from the product and could be reused for 5 cycles.
Development of Axially Chiral Styrene-Type Carboxylic Acid Ligands via Palladium-Catalyzed Asymmetric C-H Alkynylation
Cui, Ru,Jin, Ruo-Xing,Li, Fei,Li, Yan,Wang, Xi-Sheng,Wu, Bing-Bing,Wu, Tian-Rui,Yang, Chi
, p. 8132 - 8137 (2021/11/01)
A weakly coordinated carboxylate-directed palladium-catalyzed atroposelective C-H alkynylation method for the development of novel axially chiral styrene-type carboxylic acids is disclosed. This transformation exhibits good yields (up to 85%), excellent enantiocontrol (up to 99% ee), and mild conditions. Notably, the synthetic utility of the resulting alkynyl carboxylic acid derivatives was demonstrated by various derivatizations as well as their potential as chiral ligands in asymmetric C-H activations.
GUANIDINE DERIVATIVES AS TRPC MODULATORS
-
Page/Page column 42-43, (2014/02/16)
The present invention is directed to guanidine derivatives as inhibitors of transient receptor potential canonical channels (TRPC channels), in particular TRPC3 and/or TRPC6 and/or TRPC7 activity, more particularly TRPC6 activity. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders mediated by TRPC channels (Formula (I))
